Stock Analysis

# Calculating The Fair Value Of Proteomics International Laboratories Limited (ASX:PIQ)

### Key Insights

• Proteomics International Laboratories' estimated fair value is AU\$1.23 based on 2 Stage Free Cash Flow to Equity
• Current share price of AU\$1.11 suggests Proteomics International Laboratories is potentially trading close to its fair value

Today we will run through one way of estimating the intrinsic value of Proteomics International Laboratories Limited (ASX:PIQ) by projecting its future cash flows and then discounting them to today's value. We will take advantage of the Discounted Cash Flow (DCF) model for this purpose. Don't get put off by the jargon, the math behind it is actually quite straightforward.

Remember though, that there are many ways to estimate a company's value, and a DCF is just one method. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model.

View our latest analysis for Proteomics International Laboratories

## The Model

We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

Generally we assume that a dollar today is more valuable than a dollar in the future, and so the sum of these future cash flows is then discounted to today's value:

#### 10-year free cash flow (FCF) forecast

 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 Levered FCF (A\$, Millions) -AU\$3.90m -AU\$1.20m AU\$2.10m AU\$3.32m AU\$4.70m AU\$6.09m AU\$7.39m AU\$8.54m AU\$9.52m AU\$10.3m Growth Rate Estimate Source Analyst x1 Analyst x1 Analyst x1 Est @ 58.30% Est @ 41.42% Est @ 29.59% Est @ 21.32% Est @ 15.53% Est @ 11.47% Est @ 8.63% Present Value (A\$, Millions) Discounted @ 6.6% -AU\$3.7 -AU\$1.1 AU\$1.7 AU\$2.6 AU\$3.4 AU\$4.2 AU\$4.7 AU\$5.1 AU\$5.4 AU\$5.5

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = AU\$28m

After calculating the present value of future cash flows in the initial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (2.0%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 6.6%.

Terminal Value (TV)= FCF2033 × (1 + g) ÷ (r – g) = AU\$10m× (1 + 2.0%) ÷ (6.6%– 2.0%) = AU\$232m

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= AU\$232m÷ ( 1 + 6.6%)10= AU\$123m

The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is AU\$151m. In the final step we divide the equity value by the number of shares outstanding. Compared to the current share price of AU\$1.1, the company appears about fair value at a 10% discount to where the stock price trades currently. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out.

## The Assumptions

The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Proteomics International Laboratories as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 6.6%, which is based on a levered beta of 0.909. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

### SWOT Analysis for Proteomics International Laboratories

Strength
• Currently debt free.
Weakness
• Shareholders have been diluted in the past year.
Opportunity
• Forecast to reduce losses next year.
• Current share price is below our estimate of fair value.
Threat
• Has less than 3 years of cash runway based on current free cash flow.

Valuation is only one side of the coin in terms of building your investment thesis, and it shouldn't be the only metric you look at when researching a company. It's not possible to obtain a foolproof valuation with a DCF model. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. For Proteomics International Laboratories, there are three additional aspects you should further research:

1. Risks: As an example, we've found 4 warning signs for Proteomics International Laboratories that you need to consider before investing here.
2. Future Earnings: How does PIQ's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
3. Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!

PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the ASX every day. If you want to find the calculation for other stocks just search here.

### Valuation is complex, but we're helping make it simple.

Find out whether Proteomics International Laboratories is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.